Loss of Spry1 reduces growth of BRAF V600 -mutant cutaneous melanoma and improves response to targeted therapy

Mitogen-activated protein kinase (MAPK) pathway activation is a central step in BRAF -mutant cutaneous melanoma (CM) pathogenesis. In the last years, Spry1 has been frequently described as an upstream regulator of MAPK signaling pathway. However, its specific role in BRAF -mutant CM is still poorly...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell death & disease 2020-05, Vol.11 (5), p.392
Hauptverfasser:	Montico, Barbara, Colizzi, Francesca, Giurato, Giorgio, Rizzo, Aurora, Salvati, Annamaria, Baboci, Lorena, Benedetti, Dania, Pivetta, Eliana, Covre, Alessia, Bo, Michele Dal, Weisz, Alessandro, Steffan, Agostino, Maio, Michele, Sigalotti, Luca, Fratta, Elisabetta
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm - drug effects Humans Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Membrane Proteins - deficiency Membrane Proteins - genetics Phosphoproteins - deficiency Phosphoproteins - genetics Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!